53results about How to "Lessen kidney damage" patented technology

The present invention relates to formulations containing cyclosporin analogs that are structurally similar to cyclosporin A, in particular isomeric mixtures of cyclosporin analogs that are structurally similar to cyclosporin A. The formulations form stable microemulsion preconcentrates and may provide superior drug bioavailability and / or may reduce one or more adverse effects associated with the administration of cyclosporin. Also disclosed are methods for using and preparing the formulations.

The present invention provides hepatoprotectant acetaminophen mutual prodrugs, which have an acetaminophen moiety covalently linked to a second moiety that may act as a hepatoprotectant against acetaminophen hepatotoxicity. Additionally, acetaminophen mutual prodrugs may have improved water solubility which may provide better suitability for parenteral and other dosage forms relative to administration of acetaminophen. Also provided are methods of treating a disease or condition that is responsive to acetaminophen (such as fever, pain and ischemic injury) using hepatoprotectant acetaminophen mutual prodrugs, as well as kits and unit dosages.

Methods for reducing kidney damage induced by radiographic contrast medium or another nephrotoxic drug or substance administered to or generated by a patient include reducing the temperature of the patient by positioning an endovascular heat exchange device in a blood vessel of the patient and adjusting the temperature of the device to cause a reduction in the patient's temperature. The patient's temperature may be reduced prior to, during, and / or after, the administration of the contrast medium. The methods may also include administering an anti-shivering mechanism to the patient to reduce shivering caused by the reduction in the patient's temperature. The methods may also include disrupting the laminarity of blood flow around the device to enhance the temperature exchange between the device and the blood flowing around the device. The endovascular heat exchange device may be an endovascular heat exchange catheter. The device may be a component of a system, which includes a temperature controller in communication with the endovascular heat exchange device to reduce the temperature of the patient to reduce the temperature of the patient's kidneys.

The invention discloses a hemoglobin-based oxygen carrier, which comprises hemoglobin, haptoglobin and polyethyleneglycol-polyester nanoparticles. Hemoglobin is connected on the surfaces of the polyethyleneglycol-polyester nanoparticles by haptoglobin. The hemoglobin-based oxygen carrier provided by the invention has no obvious toxicity on the cells, the blood plasma does not have obvious free hemoglobin in the blood plasma after the hemoglobin-based oxygen carrier is infused, and no hypertension reaction is produced, so that the defect that the traditional hemoglobin-based oxygen carrier is high in side effects is overcome. The hemoglobin-based oxygen carrier has a good application prospect and a economic benefit.

The invention discloses an application of diacerein to prepare medicines for preventing and treating diabetic nephropathy. Diacerein is taken as a raw material of an active pharmaceutical ingredient and combined with a pharmaceutically-acceptable adjuvant to prepare a pharmaceutical composition for preventing and treating diabetic nephropathy, wherein the composition contains an effective treatment dose of the diacerein and a pharmaceutically-acceptable carrier. A research on studying the diacerein capability of protecting a diabetic rat kidney through adopting streptozotocin to induce an experimental diabetic rat model accidentally discovers that the diacerein can reduce the glycated hemoglobin level and urinary albumin excretion rate of the blood of the diabetic rat, inhibits renal cortex protein non-enzyme advanced glycation end products from forming and improves renal pathology and lesion.

The present invention provides hepatoprotectant acetaminophen mutual prodrugs, which have an acetaminophen moiety covalently linked to a second moiety that may act as a hepatoprotectant against acetaminophen hepatotoxicity. Additionally, acetaminophen mutual prodrugs may have improved water solubility which may provide better suitability for parenteral and other dosage forms relative to administration of acetaminophen. Also provided are methods of treating a disease or condition that is responsive to acetaminophen (such as fever, pain and ischemic injury) using hepatoprotectant acetaminophen mutual prodrugs, as well as kits and unit dosages.

This invention belongs to the field of biotechnology detection, particularly relates to a triple kit for early warning, treatment process and monitoring after treatment of renal failure, and further discloses a preparation method and application thereof. Serum cystatin (CysC), neutrophil gelatinase-associated lipocalin (NAGL) and C reactive protein (CRP) are used as detecting markers. The triple kit uses NGAL-CysC-CRP triple antibody as the markers, can effectively monitor the risk of renal failure, especially plays an unexpected effect of monitoring of acute renal failure of persons subjected to a traffic accident, and is high in diagnosis sensitivity of acute renal failure, and strong in specificity, the clinical monitoring accuracy is as high as 95%, and the triple kit can make nephropathy self testing and monitoring of persons with diabetes possible, is used for kidney disease early warning, can timely prevent deterioration of the patient's condition, and reduces the patient's degree of kidney damage.

The present invention is directed to a pet food and its use in reducing renal damage in companion animals. More particularly, the pet food maintains muscle mass in animals with renal conditions or animals at risk for developing a renal condition.

The invention provides a traditional Chinese medicine composition for treating primary nephrotic syndrome. The traditional Chinese medicine composition comprises the following active pharmaceutical ingredients: membranous milkvetch root, liquorice root, epimedium herb, medicinal Indianmulberry root, flastem milkvetch seed, sappan wood, cowherb seed, zedoary tumeric, common anemarrhena rhizome, amur corktree bark, barbed skullcap herb, radix salviae miltiorrhizae, rice bean, common yam rhizome, manyprickle acanto-panax root, gordon euryale seed, rhizome, sharpleaf galangal fruit, fourstamen stephania root, walnut kernel, glabrous greenbrier rhizome, sinkiang arnebia root, sevenlobed yam rhizome, cochinchnese asparagus root, belvedere fruit, medcinal evodia fruit, lychee seed, dendrobium, glossy privet fruit and Chinese angelica. The traditional Chinese medicine composition provided by the invention is used for treating the primary nephrotic syndrome, can antagonize the side effects of hormones and other Western medicines, improve the blood flow of kidney, reduce urine proteins, retard kidney damages, improve the hypercoagulable state of a patient, consolidate efficacy, reduce the rebound phenomenon of the disease and realize few side effects, low recurrence rate and high complete relief rate, and has a certain efficacy for treating the primary nephrotic syndrome.

The invention relates to a capsule for clearing away turbid and tonifying kidneys. The capsule is prepared from the following raw materials by weight: 100g of cordyceps sinensis, 1400g of astragalus membranaceus, 280g of root of red-rooted salvia, 280g of flowers carthami, 280g of spina date seeds, 500g of semen cuscutae and 100g of rheum officinale. The applied capsule for clearing away turbid and tonifying the kidneys is used for treating both deficiency and excess and treating both symptoms and root causes, is accurate in curative effect, rigorous in formula, and simple and convenient to prepare, and has a broad application prospect.

The invention relates to a schisandra chinensis-oyster dealcoholic liver-protecting health medicine and a preparation method thereof. According to the invention, schisandra chinensis and oyster are adopted in compatibility and prepared into a health medicine with dealcoholic and liver-protecting main effects, and oyster extract taken as a major medicine, schisandra chinensis extract, microcrystal cellulose, a filling agent, CMS-Na, an internal disintegrating agent, a water wetter and talcum powder are prepared into the schisandra chinensis-oyster dealcoholic liver-protecting health medicine. Excessive drinking can do a certain harm to health, so that definite effects of the schisandra chinensis-oyster dealcoholic liver-protecting health medicine on multiple complications, such as hepatic damage, cardia-cerebrovascular diseases, stomachache, obesity and hyperlipemia, of alcoholism need to be contained; and the schisandra chinensis-oyster dealcoholic liver-protecting health medicine adopts schisandra chinensis and oyster and also pays attention to concomitant symptoms of drinking, so that the aim of relieving both primary and secondary symptoms is achieved.

The invention discloses an oxygen carrier based on a hemoglobin-haptoglobin compound and a preparation method of the oxygen carrier. The oxygen carrier comprises haptoglobin, hemoglobin, antioxidant and pyridoxal phosphate. The hemoglobin-haptoglobin compound is formed as a unit for bringing the oxygen carrying activity into play by virtue of special combination ability of the haptoglobin and the hemoglobin. The oxygen carrier based on the hemoglobin-haptoglobin compound disclosed by the invention is free of hypertension reaction after being infused, and capable of protecting an isolated heart. And therefore, the oxygen carrier can be used for clinical blood transfusion, protecting vital organs including the heart and the like from ischemia reperfusion injuries, and has good application prospects and economical benefits.

The invention relates to application of oleanolic acid in preparation of drugs for treatment autoimmune diseases, and belongs to the technical field of biomedicine. The oleanolic acid can inhibit thefunction of the transcription factor ROR[gamma]t, inhibit the differentiation of Th17 cells, and inhibit the transcriptional expression of the target genes IL-17A and IL-17F of ROR[gamma]t at the RNAlevel, and inhibit IL-17A cytokines. The secretion inhibits the level of anti-dsDNA antibodies in the serum; the oleanolic acid of the present invention has an obvious Th17 cell activity inhibitory function, and provides a lead structure for the development of new drugs for the treatment of autoimmune diseases.

The invention relates to a compound recipe kidney-strengthening tablet for enlivening the spleen and strengthening kidney in the traditional technique field. The preparing method comprises the following steps: disintegrating rhubarb horsetails into the powder; collating after immersing; collecting the collation liquid; disintegrating radix salvia miltiorrhiza, astragalus root, extractum glycyrrhizae liquidum and hirudo into the powder; extracting with alcohol reflux; filtering; merging the filtering liquid and the collation liquid; mixing uniformly; concentrating into the dense plaster; getting the extract of five tastes medicine; adding fermenting Cordyceps sinensis bacterial powder, crystalline cellulose, sodium carboxymethylstarch, starch and dolomol; mixing uniformly; getting the product by pelleting. The invention can reduce BUN and SCr level, which improves plasma protein content, improves the nutrient state, accelerates the renovation and the reactivation of nephric tubule epithelial cell, corrects the metabolic disorder of amino acid, protein and lipid, adjusts the cell immunity, improves the immunity, protects and recovers the kidney function, and prevents secondary infection.

The invention belongs to the field of biopharmacology, and relates to a purpose of hydrogen gas to preparation of renal fibrosis treatment medicine, in particular to a purpose of hydrogen gas to preparation of medicine for treating renal fibrosis caused by chronic nephrosis. A built animal model is subjected to biochemical index detection, isolated cell study, western blotting experiments, immunohistochemistry and data analysis after hydrogen gas intervening; the result shows that the hydrogen gas can realize the fibrosis inhibition on the pathological environment induction through an sirt1 path; the harm to the renal function unit in the fibrosis process is reduced through improving the sirt1; and the hydrogen gas can be further used for preparing a medicine preparation for treating renalfibrosis, particularly the renal fibrosis caused by chronic nephrosis.

The invention relates to ethanol extracting solution of desmodium renifolium and an application thereof and belongs to the field of medicines. The ethanol extracting solution has the beneficial effects that the desmodium renifolium as a Dai medicine has an effect of preventing and treating chronic renal failure, and the mechanism is associated with improvement of renal anemia of a rat with chronicrenal failure and reduction of renal injury and renal interstitial fibrosis degree. The invention provides an application direction of the desmodium renifolium, the ethanol extracting solution and water extracting solution thereof in preventing and treating the chronic renal failure, provides a preparation method of desmodium renifolium tablets and provides pharmacodynamic basis for further research and development of the desmodium renifolium tablets.

The invention discloses a pharmaceutical composition for treating chronic nephritis. The pharmaceutical composition is prepared from the following raw materials: fructus schizandrae, rhizoma chuanxiong, astragalus, epimedium, glossy privet fruit, poria cocos, dandelion, herba houttuyniae, cortex magnoliae officinalis, semen lablab album, campsis grandiflora, cassia twig, fructus aurantii immaturus, spreading hedyotis herb, rhizoma imperatae, cortex mori radicis, salviae miltiorrhizae, semen ziziphi spinosae, semen cuscutae, atractylodes lancea, rhizoma alismatis, monkshood, radix glycyrrhizae and peach seeds. The pharmaceutical composition disclosed by the invention is strict in components, simple and convenient in preparation, exact in curative effective of treating chronic nephritis and wide in prospect.

The invention relates to a medicine composition for treating nephropathy. The medicine is prepared from herba epimedii, frangrant ainsliaea herb, polygonum multiflorum, honeysuckle, myrrh, dandelions, oriental wormwood, coptis chinensis, the root of kudzu vines, teasel roots, the root of bidentate achyranthes, radix stemonae, cinnamon, rhizoma atractylodis, radix paeoniae alba, Chinese yams, ginkgo leaves, burdock, rohdea japonica, pepper, acanthopanax, rhizoma acori graminei, golden cypress, rhizoma alismatis and peach kernels. The medicine composition treats both symptoms and root causes of chronic nephrosis in a deficiency and excess mode, the curative effect is definite, the formulation is precise, preparation is easy and convenient, and broad application prospects are achieved.

The invention relates to a novel medicine application of human urinary kallidinogenase, i.e. the application of the human urinary kallidinogenase in preparing medicine for treating diabetic nephropathy.

The invention relates to a medicine composition of cefpiramide sodium and infant compound amino acid injection (19AA-I), and particularly relates to combined application packaging of the medicine composition of the cefpiramide sodium and the infant compound amino acid injection (19AA-I). The medicine composition of the cefpiramide sodium and the infant compound amino acid injection (19AA-I) comprises the cefpiramide sodium for injection and the infant compound amino acid injection (19AA-I). Compared with the mixing use manner of cefpiramide sodium and infant compound amino acid injection (19AA-I), the combined application packaging of the medicine composition has the advantages that steps are simplified, the safety of children medication is improved, the stability of the cefpiramide sodium is greatly benefitted, and the clinical application quality and the biological availability of the medicine are improved.

Methods for reducing kidney damage induced by radiographic contrast medium or another nephrotoxic drug or substance administered to a patient include reducing the temperature of the patient by positioning an endovascular heat exchange device in a blood vessel of the patient and adjusting the temperature of the device to cause a reduction in the patient's temperature. The patient's temperature may be reduced prior to, during, and / or after, the administration of the contrast medium. The methods may also include administering an anti-shivering mechanism to the patient to reduce shivering caused by the reduction in the patient's temperature. The methods may also include disrupting the laminarity of blood flow around the device to enhance the temperature exchange between the device and the blood flowing around the device. The endovascular heat exchange device may be an endovascular heat exchange catheter. The device may be a component of a system, which includes a temperature controller in communication with the endovascular heat exchange device to reduce the temperature of the patient to reduce the temperature of the patient's kidneys.

The invention relates to caterpillar fungus stilbene ginseng capsule. The caterpillar fungus stilbene ginseng capsule is prepared from the following raw materials by weight: 140g of caterpillar fungus, 1,400g of astragalus membranaceus, 560g of salviae miltiorrhizae, 560g of safflower and 280g of spina date seed. The caterpillar fungus stilbene ginseng capsule disclosed by the invention treats both principal and secondary aspects of chronic nephritis, is easy to prepare, has an exact treatment effect, is based on a rigorous formula and has a wide application prospect.

The invention relates to a medicine preparation for treating chronic nephrosis. The medicine preparation is prepared from the following raw materials: epimedium, obovate ainsliaea, polygonum multiflorum, lonicera japonica, myrrh, dandelion, herba artemisiae scopariae, coptis chinensis, kudzu vine root, radix dipsaci, radix achyranthis bidentatae, radix stemonae, cinnamon, rhizoma atractylodis, radix paeoniae alba, Chinese yam, gingko leaves, burdock, rohdea japonica, pepper, manyprickle acanthopanax root, rhizoma acori graminei, cortex phellodendri, rhizoma alismatis and peach kernels. The medicine preparation can be used for treating both symptoms and root causes of chronic nephrosis, has the advantages of exact curative effect, strict prescription and convenient preparation, and has a wide application prospect.

The invention relates to the technical field of medicine and food processing, in particular to a uric acid reducing composition containing rosemary, a uric acid reducing health-care product and a uric acid reducing medicine, wherein the uric acid reducing composition containing the rosemary comprises a rosemary extract, a dandelion extract, a lily extract and a peony root extract. According to the invention, the rosemary extract, the dandelion extract, the lily extract and the peony root extract are used as functional raw materials; scientific compatibility is achieved; all the components play a synergistic role; auxiliary materials are reasonably matched; and the uric acid reducing effect is remarkable. Experiments prove that, compared with a single extract, the composition disclosed by the invention has a stronger uric acid reducing effect; and, compared with common uric acid reducing medicines, the composition disclosed by the invention does not cause liver and kidney injury, and is milder and safer in uric acid reducing effect.

The invention relates to a medicine for preventing and treating the epidemic hemorrhagic fever. The medicine comprises the active pharmaceutical ingredients of ribavirin, prednisone and enalapril, and the three active pharmaceutical ingredients produce a synergetic effect. The medicine effectively kills the virus, the attach time of the symptom is remarkably shortened, the crossing stage rate is increased, the occurrence rate of the complication is reduced, and the treatment needs of a patient are better met.

The invention relates to the technical field of electronic nephroscopes, and discloses a flexible electronic nephroscope with a bendable tail end, the flexible electronic nephroscope comprises a nephroscope body, a light source and a camera shooting integrated system, the light source and the camera shooting integrated system are matched with the nephroscope body, the nephroscope body comprises a nephroscope pipe and a handle nephroscope operation part, the nephroscope pipe comprises a main hose, and the left end of the main hose is fixedly connected with a bending part protection pipe; a bending assembly is arranged in the bending part protection pipe, a control mechanism used for controlling the bending assembly is arranged in the handle operation part, the bending assembly comprises a bending snake bone, the left end and the right end of the bending snake bone are fixedly connected with a left end piece and a right end piece respectively, and a turning wheel is driven to rotate by shifting a corner knob. According to the flexible electronic nephroscope with the bendable tail end, the flexible steel wire can pull one end of the left end piece, the bent snake bone drives the nephroscope pipe to be bent, the active bending part of the nephroscope pipe is bent in the front direction and the back direction, the bending angle is 200 + / -10 degrees, bending is free of damping, the nephroscope can conveniently reach the renal pelvis and all renal calyces, and no dead angle is left for stone breaking and removing.

The invention relates to a chelator for internal contamination of radionuclide strontium. The chelator comprises raw materials in parts by mass as follows: 0.6-0.8 parts of CTS-EDTA nanoparticles, 0.08-0.12 parts of calcium dobesilate, 8-10 parts of normal saline (0.85-0.9wt%) and a proper amount of a monopotassium phosphate-sodium hydroxide buffer solution. The chelator for internal contamination of the radionuclide strontium can effectively chelate the radionuclide strontium in skeletons, intravenous administration is performed twice in a mouse test, the discharge rate of the radionuclide strontium in the skeletons after 3 d is higher than 97%, and the accumulated amount of the radionuclide strontium in the skeletons is greatly decreased; the content of protein in proteinuria caused by the radionuclide is decreased by more than 60%, so that the renal injury is obviously reduced.

The invention relates to a traditional Chinese medicine brown ginseng preparation for anti-tumor assistant treatment, which includes, by weight, 270-330 g of brown ginseng, 30-80 g of astragalus membranaceus, 70-130 g of panax-notoginseng, 80-120 g of ground beetles, 30-50 g of pericarpium citri reticulatae, 70-130 g of radix bupleuri, 90-110 g of lotus seed extract, and 80-120 g of lucid ganoderma. The brown ginseng is produced in Fusong of the northeast and is mainly planted in low mountains being lower than 300-800 m in elevation. The brown ginseng is suitable for annual average temperatureof 2.4-13.9 DEG C and loves cold and wet weathers. The brown ginseng preparation is simple in preparation method and has no toxic and side effects, can effectively improve postoperative recovery of tumor patient, improves immunity and has inhibition effect on tumors. By replication of an malignant tumor animal model and supplement of pharmacodynamics and toxicologic informations of tumor immunotherapy of special-purpose ginseng polysaccharides and saponins, the preparation can supply evidence for tumor assistant treatment.

The invention relates to a pharmaceutical composition containing ceftizoxime sodium and pediatric compound amino acid injection (19AA-I), in particular to a combined application package. The pharmaceutical composition contains ceftizoxime sodium and pediatric compound amino acid injection (19AA-I). Compared with the matching and mixing use of ceftizoxime sodium and pediatric compound amino acid injection (19AA-I), the combined application package has the advantages that the steps are simplified, the pediatric medication security is improved, the stability of ceftizoxime sodium is greatly facilitated, and the clinical application quality and bioavailability of the medicine can be improved.